Dybbs Michael 4

What Happened

• Michael Dybbs, a director of Sutro Biopharma (STRO), was granted a 10,000-share derivative award on June 5, 2026. The award is reported at $0.00 on the Form 4 (derivative grant), meaning it was a grant of equity rights (e.g., options or RSUs) rather than an open-market purchase or sale.

Key Details

• Transaction date: June 5, 2026; Form 4 filed: June 9, 2026 (filed within the 2-business-day window).
• Transaction type/code: A — grant/award (derivative).
• Shares/units granted: 10,000; reported acquisition price: $0.00; reported acquisition value: $0.
• Shares owned after transaction: Not specified in the information provided in this summary.
• Footnote (vesting): The award vests monthly at 8.33% of the total each month, with the first tranche vesting July 5, 2026, and fully vesting on the earlier of the issuer's 2027 annual meeting or June 5, 2027.

Context

• This was a director equity award (a common form of compensation for board members). It does not reflect an open-market purchase or a sale and does not indicate immediate cash proceeds — it simply grants future rights that vest over time. For retail investors, director grants are routine compensation and should be weighed with other insider activity and company fundamentals.